Prognosis in patients with hepatocellular carcinoma correlates to mutations of p53 and/or hMSH2 genes

Yano Masatsugu

Hamatani Kiyohiro

Eguchi Hidetaka

Hirai Yuko

MacPhee Donald G.

Sugino Keizo

Dohi Kiyohiko

Itamoto Toshiyuki

Asahara Toshimasa

European Journal of Cancer

Association of gene alterations and prognosis has not fully been elucidated in hepatocellular carcinoma (HCC). To clarify the relationship between p53 and hMSH2 mutations and prognosis, we analysed these mutations in 83 HCC cases and assessed their association with various clinicopathological factors. The 3-year disease-free survival (DFS) or overall survival (OS) rates in HCC patients with p53 mutation and p53 wild/hMSH2 mutation significantly decreased compared with those without these mutations (14.3-0x1.f824p+0nd 37.5% versus 67.5-0.000000or DFS; 35.7-0x1.f5cf80852f11p+0nd 50.0% versus 96.4-0.000000or OS, respectively). In the multivariate analysis, categories by p53 and hMSH2 mutation status, and liver cirrhosis demonstrated statistical significances for DFS and OS. Moreover, the frequency of patients with p53 and/or hMSH2 mutations in intrahepatic metastasis (75.0%) was significantly higher than that in multicentric occurrence (14.3%). Thus, p53 and hMSH2 mutations will be useful for identifying subsets of HCC patients with poor prognosis.

p53 gene

hMSH2 gene

Hepatocellular carcinoma

Intrahepatic metastasis

Multicentric occurrence

医学 [ 490 ]

英語

Elsevier Ltd

Copyright (c) 2007 Elsevier Ltd

[ISSN] 0959-8049

[DOI] 10.1016/j.ejca.2007.01.032

[NCID] AA1075407X

[PMID] 17350822

[DOI] http://dx.doi.org/10.1016/j.ejca.2007.01.032 ～の異版である